These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19488079)

  • 21. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
    Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
    Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
    Ho TW; Ho AP; Chaitman BR; Johnson C; Mathew NT; Kost J; Fan X; Aurora SK; Brandes JL; Fei K; Beebe L; Lines C; Krucoff MW
    Headache; 2012 Feb; 52(2):224-35. PubMed ID: 22221076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs for migraine.
    Stovner LJ; Tronvik E; Hagen K
    J Headache Pain; 2009 Dec; 10(6):395-406. PubMed ID: 19795182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
    Villalón CM; Olesen J
    Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcitonin gene-related peptide receptor antagonists for migraine.
    Fischer MJ
    Expert Opin Investig Drugs; 2010 Jul; 19(7):815-23. PubMed ID: 20482328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CGRP receptor antagonists: an expanding drug class for acute migraine?
    Negro A; Lionetto L; Simmaco M; Martelletti P
    Expert Opin Investig Drugs; 2012 Jun; 21(6):807-18. PubMed ID: 22512641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine: a response.
    Ho TW; Bigal M
    Headache; 2011 Apr; 51(4):617-8. PubMed ID: 21457247
    [No Abstract]   [Full Text] [Related]  

  • 28. The tortuous road to an ideal CGRP function blocker for the treatment of migraine.
    Davis CD; Xu C
    Curr Top Med Chem; 2008; 8(16):1468-79. PubMed ID: 18991732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimigraine efficacy of telcagepant based on patient's historical triptan response.
    Ho TW; Olesen J; Dodick DW; Kost J; Lines C; Ferrari MD
    Headache; 2011 Jan; 51(1):64-72. PubMed ID: 21054362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
    Connor KM; Shapiro RE; Diener HC; Lucas S; Kost J; Fan X; Fei K; Assaid C; Lines C; Ho TW
    Neurology; 2009 Sep; 73(12):970-7. PubMed ID: 19770473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Migraine can signal a risk for heart and brain].
    Vetter C
    MMW Fortschr Med; 2009 Sep; 151(37):17. PubMed ID: 19827419
    [No Abstract]   [Full Text] [Related]  

  • 32. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
    Ho TW; Connor KM; Zhang Y; Pearlman E; Koppenhaver J; Fan X; Lines C; Edvinsson L; Goadsby PJ; Michelson D
    Neurology; 2014 Sep; 83(11):958-66. PubMed ID: 25107879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CGRP antagonists: novel concept for treatment of migraine].
    Nieber K
    Med Monatsschr Pharm; 2009 May; 32(5):182-5. PubMed ID: 19469188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcitonin gene-related peptide and migraine. Increases understanding of physiopathology can lead to new drug therapy].
    Edvinsson L
    Lakartidningen; 2010 Dec 15-21; 107(50):3208-11. PubMed ID: 21294334
    [No Abstract]   [Full Text] [Related]  

  • 35. [Gepants: the beginning of a new age in the symptomatic treatment of migraine?].
    Pascual-Gómez J
    Rev Neurol; 2009 Apr 1-15; 48(7):337-8. PubMed ID: 19319812
    [No Abstract]   [Full Text] [Related]  

  • 36. CGRP receptors in the control of pain and inflammation.
    Benemei S; Nicoletti P; Capone JG; Geppetti P
    Curr Opin Pharmacol; 2009 Feb; 9(1):9-14. PubMed ID: 19157980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.
    Ho TW; Ho AP; Ge YJ; Assaid C; Gottwald R; MacGregor EA; Mannix LK; van Oosterhout WP; Koppenhaver J; Lines C; Ferrari MD; Michelson D
    Cephalalgia; 2016 Feb; 36(2):148-61. PubMed ID: 25926620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
    Dodick DW; Kost J; Assaid C; Lines C; Ho TW
    Cephalalgia; 2011 Feb; 31(3):296-300. PubMed ID: 20937606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CGRP-receptor antagonism in migraine treatment.
    Edvinsson L
    Lancet; 2008 Dec; 372(9656):2089-90. PubMed ID: 19036426
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment.
    Kuzawińska O; Lis K; Cessak G; Mirowska-Guzel D; Bałkowiec-Iskra E
    Neurol Neurochir Pol; 2016; 50(6):463-467. PubMed ID: 27553188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.